Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

A 2-center review of histopathology of variants of upper urinary tract urothelial carcinoma and their impact on clinical outcomes.

Urologic oncology·2024

Same author

Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

[Instillation therapies for urothelial carcinoma of the upper urinary tract].

Der Urologe. Ausg. A·2019

Same author

[Therapeutic management of blunt testicular trauma].

Der Urologe. Ausg. A·2017

Search research articles

Related Experiment Video

Updated: May 25, 2026

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

[Bone metastasis in prostate cancer].

F Moltzahn¹, G N Thalmann

¹Urologische Universitätsklinik, Inselspital Bern, Anna-Seiler-Haus, Freiburgstraße 10, CH-3010 Bern, Schweiz.

Der Urologe. Ausg. A

|January 20, 2012

Summary

This summary is machine-generated.

Denosumab, a RANKL inhibitor, is more effective than zoledronic acid in preventing skeletal events in prostate cancer bone metastases. It offers advantages in renal clearance and administration, though long-term safety data are still limited.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Related Experiment Videos

Last Updated: May 25, 2026

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Area of Science:

Oncology
Pharmacology

Context:

Prostate cancer frequently metastasizes to bone, causing significant morbidity and reduced quality of life.
Skeletal-related events (SRE) are a major complication, necessitating effective preventative strategies.

Purpose:

To compare the efficacy and safety of denosumab versus zoledronic acid in preventing SRE in prostate cancer patients with bone metastases.
To review emerging therapies targeting bone metastasis in prostate cancer.

Summary:

Denosumab, a monoclonal antibody targeting RANKL, demonstrated superiority over zoledronic acid in preventing SRE and prolonging bone metastasis-free survival.
Unlike zoledronic acid, denosumab's clearance is independent of renal function and it is administered subcutaneously.
Both treatments showed similar toxicity profiles, but long-term denosumab data are limited.

Impact:

Denosumab offers a potentially more convenient and effective option for managing bone metastases in prostate cancer.
This review highlights the evolving landscape of bone-targeted therapies and the importance of comparative effectiveness research.